1310P - Loratadine: A potential game-changer in lung cancer treatment with improved survival outcomes

Background

Tumor-associated inflammation suggests that anti-inflammatory medication could be beneficial in cancer therapy. Loratadine, an antihistamine, has demonstrated improved survival in certain cancers. This study investigates loratadine's anticancer mechanisms in lung cancer. Tumor-associated inflammation suggests that anti-inflammatory medication could be beneficial in cancer therapy. Loratadine, an antihistamine, has demonstrated improved survival in certain cancers. This study investigates loratadine's anticancer mechanisms in lung cancer.

Methods

A retrospective cohort of 4,522 lung cancer patients from 2006 to 2018 was analyzed to identify non-cancer drug exposures associated with prognosis. Cellular experiments, animal models, and RNAseq data analysis were employed to validate findings and explore the antitumor effects of loratadine.

Results

The retrospective study revealed a positive association between loratadine use and improved lung cancer survival. Cellular assays showed that moderate loratadine doses induced apoptosis, cellular senescence, and reduced epithelial-mesenchymal transition (EMT). Interestingly, high loratadine doses triggered pyroptosis and interacted with apoptosis through caspase-8. Animal models indicated that loratadine impeded tumor growth in C57BL/6 mice but not in nude mice xenografts, suggesting potential immune response involvement in apoptosis and pyroptosis.

Conclusions

Loratadine use is linked to enhanced survival in lung cancer patients, potentially due to its role in modulating cell death, inflammatory, and immune responses by regulating the interplay between apoptosis and pyroptosis via caspase-8. Further research on other antihistamines and their immune response to tumors is warranted.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

China National Science Foundation (grant number 82022048 & 81871893), the Key Project of Guangzhou Scientific Research Project (grant number 201804020030).

Disclosure

All authors have declared no conflicts of interest.